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Infection with the hepatitis C virus is a major 
health  burden  worldwide  (Alter  and  Seeff, 
2000; Lauer and Walker, 2001). The virus per-
sists in the majority of infected persons, although 
a significant minority of individuals is able to 
spontaneously control viral replication, as indi-
cated by lack of detectable viremia over years of 
follow up (Takaki et al., 2000). The exact mech-
anisms that lead to these distinct outcomes have 
not been fully defined, but the presence or ab-
sence of a vigorous and multispecific proliferative 
CD4+ T cell response against hepatitis C virus 
(HCV) proteins is a strong immunological corre-
late of the outcome of acute HCV infection 
(Diepolder et al., 1995, 1996; Chang et al., 
2001; Day et al., 2002; Grakoui et al., 2003; 
Rehermann, 2009). Proliferative HCV-specific 
CD4+ T cell responses are usually not detect-
able in acute persisting and chronic HCV in-
fection (Chang et al., 2001; Day et al., 2002; 
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Vigorous proliferative CD4+ T cell responses are the hallmark of spontaneous clearance of 
acute hepatitis C virus (HCV) infection, whereas comparable responses are absent in chroni-
cally evolving infection. Here, we comprehensively characterized the breadth, specificity, 
and quality of the HCV-specific CD4+ T cell response in 31 patients with acute HCV infec-
tion and varying clinical outcomes. We analyzed in vitro T cell expansion in the presence  
of interleukin-2, and ex vivo staining with HCV peptide-loaded MHC class II tetramers. 
Surprisingly, broadly directed HCV-specific CD4+ T cell responses were universally detect-
able at early stages of infection, regardless of the clinical outcome. However, persistent 
viremia was associated with early proliferative defects of the HCV-specific CD4+ T cells, 
followed by rapid deletion of the HCV-specific response. Only early initiation of antiviral 
therapy was able to preserve CD4+ T cell responses in acute, chronically evolving infection. 
Our results challenge the paradigm that HCV persistence is the result of a failure to prime 
HCV-specific CD4+ T cells. Instead, broadly directed HCV-specific CD4+ T cell responses are 
usually generated, but rapid exhaustion and deletion of these cells occurs in the majority of 
patients. The data further suggest a short window of opportunity to prevent the loss of 
CD4+ T cell responses through antiviral therapy.
© 2012 Schulze zur Wiesch et al.  This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six   
months after the publication date (see http://www.rupress.org/terms). After 
six months it is available under a Creative Commons License (Attribution–
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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methods within months of the acute infection. Of note, early 
initiation of antiviral treatment was able to protect HCV-
specific  CD4+  T  cells  from  complete  deletion.  Our  data 
demonstrate that HCV infection generally induces a broadly 
directed HCV-specific CD4+ T cell response that is short-
lived in the majority of subjects. Future research needs to 
elucidate the mechanisms of secondary CD4+ T cell failure 
(Diepolder, 2009) and the fate of HCV-specific CD4+ T cells 
in persisting viremia.
RESULTS
Multispecific HCV CD4+ T cell responses are universally 
detectable during acute HCV infection despite absent LPA 
responses in acute chronically evolving (AC) HCV
The virus-specific CD4+ T cell response during acute HCV 
infection has not been well characterized beyond prolifera-
tive responses against whole HCV proteins. We therefore 
performed a comprehensive assessment of the early HCV-
specific CD4+ T cell response using different technologies in 
a large cohort of 31 acutely infected patients: 18 patients who 
went on to spontaneously resolve infection, and 13 patients 
with acute, chronically evolving infection. Clinical charac-
teristics of the patients are summarized in Table I.
For direct comparison, we initially performed 6-d LPAs, 
the historic “standard” for the analysis of CD4+ T cell re-
sponses (Diepolder et al., 1995; Rosenberg et al., 1997; Lauer 
et  al.,  2002),  using  recombinant  HCV  proteins  and  fresh 
PBMCs from the earliest time point for which PBMCs were 
available for 29 of the 31 patients, all within the first 6 mo 
after onset of symptoms (Table I). In accordance with many 
immunological  studies  of  acute  infection  (Gerlach  et  al., 
1999; Urbani et al., 2006; Kaplan et al., 2007), we detected 
strong proliferative responses against all of the HCV non-
structural antigens in patients with AR HCV. These responses 
were mostly absent in patients with acute, chronically evolv-
ing HCV (mean NS3 stimulation index [SI] in acute resolv-
ers 15 vs. 2.1 in AC infection, P < 0.0017; NS4 SI 13.2 vs. 
3.2, P < 0.016; NS5 SI 7.15 vs. 1.93 P < 0.0026; Fig. 1 A).
We had previously demonstrated that we can define the 
HCV-specific CD4+ T cell response in subjects with resolved 
infection on a single epitope level using short-term in vitro 
culture with HCV proteins and a comprehensive, overlap-
ping HCV peptide set covering the entire HCV genome   
under supplementation of rIL-2 (Day et al., 2002; Schulze 
zur Wiesch et al., 2005, 2007). Using this approach, we next 
tested all subjects with acute HCV infection using PBMCs 
from the first available time point (≤ 6 mo after onset of 
symptoms; median, 57 d; range, 3–179; Table I); all pa-
tients were treatment naive at the time of analysis. We detected 
broad responses in almost all individuals, with between 1 and 
26 HCV CD4+ T cell epitopes targeted.
In contrast to the negative results observed in the standard 
LPA assay, all 13 patients with chronic evolution of acute 
HCV infection demonstrated CD4+ T cell responses, with 
most subjects displaying broad reactivity against numerous 
CD4+ T cell epitopes (range, 1–18 specificities; Fig. 1, A–D). 
Gerlach et al., 1999; Shoukry et al., 2004; Schulze zur 
Wiesch et al., 2005), with the exception of chronically in-
fected patients who previously resolved an HCV infection 
with a heterologous HCV genotype (Schulze Zur Wiesch   
et al., 2007). The analysis of HCV-specific CD4+ T cells has 
historically relied on standard tritium uptake lymphoprolifer-
ative assays using whole HCV proteins, yielding very limited 
information about the breadth and fine specificities of the 
HCV-specific CD4+ T cell response (Diepolder et al., 1995; 
Missale et al., 1996; Gerlach et al., 1999; Kamal et al., 2004; 
Rahman et al., 2004; Lauer et al., 2005). The standard lym-
phoproliferative assay (LPA) is also dependent on in vitro 
proliferation of T cells. Hence, a negative result does not 
preclude the presence of antigen-specific cells nor does the 
test assess frequencies and phenotypic properties of the T cells 
of interest. A few studies using direct ex vivo techniques, 
such as cytokine ELISpot or class II tetramer staining, have 
also suggested a limited presence of HCV-specific CD4+ 
T  cells  in  patients  developing  chronic  infection,  but  lack   
either  detail  or  comprehensiveness  (Day  et  al.,  2003; 
Ulsenheimer et al., 2006; Urbani et al., 2006; Semmo and   
Klenerman, 2007; Smyk-Pearson et al., 2008). Thus, it   
remains unclear whether the absence of CD4+ proliferative 
responses observed during acute persistent HCV infection is 
indicative of a complete lack of priming of HCV-specific 
CD4+ T cells, or whether HCV-specific CD4+ T cells are 
present, but are functionally deficient (Diepolder, 1995, 2009; 
Thimme et al., 2001; Shoukry et al., 2004; Klenerman and 
Hill, 2005; Day et al., 2006; Folgori et al., 2006; Chang, 
2007;  Urbani  et  al.,  2008;  Golden-Mason  et  al.,  2009;   
Nakamoto et al., 2009).
This study combines novel approaches to comprehen-
sively analyze the virus-specific CD4+ T cell response with 
high resolution in a large and well-defined cohort with acute 
HCV infection to test the hypothesis that HCV persistence is 
associated with an absence of virus-specific CD4+ T cell re-
sponses. HCV-specific CD4+ T cells were analyzed using the 
following techniques: (a) standard tritium uptake LPAs against 
recombinant HCV proteins; (b) single-peptide intracellular 
cytokine secretion assays of in vitro expanded HCV-specific 
CD4+ T cell lines; and (c) ex vivo class II tetramer analyses with 
tetramers restricted by several different DR molecules [eight 
different HCV class II tetramers for epitopes restricted by five 
different molecules (DRB1*0101, DRB1*0401, DRB0*404, 
DRB1*1101, and DRB1*1501)].
When using advanced CD4+ T cell assays, we find that 
broadly directed HCV-specific CD4+ T cells are universally 
detectable during early stages of infection, regardless of out-
come. We also find a similar repertoire of targeted epitopes 
in all subjects. In chronically evolving HCV infection, we 
find that HCV-specific CD4+ T cells show early functional 
defects that are partially reversible in vitro by addition of   
exogenous recombinant IL-2 (rIL-2) at early stages of infec-
tion. In addition, the CD4+ T cell response rapidly collapses 
in vivo in the presence of persistent HCV viremia and be-
comes completely undetectable by the most sensitive detection JEM Vol. 209, No. 1 
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Table 1.  Clinical and immunological characteristics of the study cohort
Label  Course of 
infection
Peak  
ALT
Age, sex Therapy Therapy 
outcome
Genoytpe Risk  
factor
First 
sample 
No of CD4+ 
responses
First 
sample VL 
Peak VL Nadir VL 
d IU/ml IU/ml IU/ml
AC1 AC 473 35, M None Chronic 1 IDU 94 2 42,000 42,000 42,000
AC2 AC 2915 20, F PEG/RBV 
24W
SVR 1a IDU 125 1 358,000 >700,000 235,000
AC3 AC 206 19, F PEG/RBV 
24W
SVR 1b IDU 49 13 2800 358,000 1080
AC4 AC 201 30, M PEG/RBV 
48W
SVR 1a IDU 107 1 7470 7470 7470
AC5 AC 720 28, M IFN 6 mIU 
tiw 48W
Relapse 1 Hospitalization 137 3 >700,000 >700,000 194,000
AC6 AC 420 26, M PEG 24W SVR 1a IDU 100 1 234,000 234,000 120,647
AC7 AC 1074 37, M PEG/RBV 
24W
SVR 1b IDU 0 13 >700,000 >700,000 +*
AC8 AC 2145 23, F PEG/RBV 
12W
SVR 1 IDU 35 17 902 902 +*
AC9 AC 678 38, M None Chronic 1 IDU 62 6 380,000 380,000 380,000
AC10 AC 308 20, F PEG/RBV 
24W
SVR  1b IDU 53 12 >700,000 >700,000 342
AC11 AC 427 40, F IFN 3 mIU 
tiw/RBV
SVR 1a Needle Stick 14 12 900 >700,000 900
AC12 AC 1074 37, M None Chronic 1a IDU 54 6 >700,000 >700,000 456,999
AC13 AC 1204 55, F PEG/RBV 
24W
SVR 2** Needle stick 7 13 >700,000 >700,000 +*
AR1 AR 2237 27, M NA NA 3** IDU 16 7 +* +* NA
AR2 AR 331 33, M NA NA NA Cocaine 41 2 +* +* NA
AR3 AR 1630 28, F NA NA 1** IDU 30 22 7215 7215 NA
AR4 AR 1673 21, F NA NA 1a IDU 7 20 >700,000 >700,000 NA
AR5 AR 443 41, F NA NA 1** Blood 
Transfusion
56 26 260,830 260,830 NA
AR6 AR 1845 38, F NA NA 1** Surgery 156 12 +* +* NA
AR7 AR 1235 31, M NA NA 1** Surgery 27 17 +* +* NA
AR8 AR 1073 42, M NA NA 1** IDU 20 5 55,700 55,700 NA
AR9 AR 918 35, F NA NA 1** Hospitalization 26 14 4000 4000 NA
AR10 AR 463 29, M NA NA 3a IDU 15 8 211,195 211,195 NA
AR11 AR 1327 47, F NA NA 1** Sexual  
Transmission
112 16 +* +* NA
AR12 AR 2235 31, F NA NA 1** Hospitalization 44 5 9700 9700 NA
AR13 AR 1694 59, F NA NA 1** Hospitalization 18 11 342000 342000 NA
AR14 AR 2659 39, F NA NA 1a IDU 12 9 734,400 734,400 NA
AR15 AR 201 23, F NA NA 1a IDU/Cocaine 14 5 3200 3200 NA
AR16 AR 1624 22, F NA NA 1** IDU 108 17 +* +* NA
AR17 AR 2435 63, F NA NA 1** Unknown 177 9 +* +* NA
AR18 AR 1060 52, F NA NA NA Sexual  
Transmission
57 5 +* +* NA
AC patient was recruited and studied within 6 mo after onset of symptoms and remained viremic after 6 mo; AR patient was recruited and studied within 6 mo after 
onset of symptoms, and tested HCV RNA negative on at least two occasions after 6 mo and later; ALT, alanine transaminase; M, male; F, female; PEG, pegylated 
interferon ; RBV, Ribavirin; tiw, three times weekly; IU, international units; IDU, intravenous drug use; VL, viral load, NA, not applicable. *, + HCV PCR, too low to 
quantify. **, serotype.64 Kinetics of T cell dysfunction in HCV infection | Schulze zur Wiesch et al.
nadir viral load and the number of targeted epitopes (r = 0.34; 
P = 0.25). These results demonstrate that HCV-specific 
CD4+ T cells are not absent in early persisting infection, but 
are usually broadly directed, though with functional deficits 
as they do not proliferate in vitro upon restimulation with 
recombinant proteins in the standard LPA assay.
The breadth of the response detected in patients with 
early AC infection was not significantly different from what 
we observed in the 18 subjects with spontaneously resolv-
ing infection (median, 10 responses; range, 2–26; P > 0.05; 
Fig. 1 B). There was also no difference between subjects with 
resolving and persistent infection in the size of the expanded 
CD4+ T cell populations as measured by intracellular cyto-
kine staining (ICS) for interferon- after stimulation with 
single HCV peptides (Fig. 1 C).
Broad responses were detectable in the majority of patients 
over a wide range of viral loads at the time point of the assay, 
with some subjects with the highest viral loads targeting 
>10 HCV CD4+ T cell epitopes (Table I). None of the sub-
jects with a chronic course of infection achieved complete 
temporary control of HCV (defined as a negative qualitative 
HCV PCR) during the observation period, an uncommon 
occurrence that has been demonstrated to be associated with 
temporary detection of CD4 responses in standard LPA 
(Gerlach et al., 1999). At the same time, partial control of 
HCV was displayed by many of the subjects at select time 
points of viremia, leading to a “yo-yo pattern,” which we and 
others have described as the most common pattern of viremia 
during acute HCV infection (Cox et al., 2009; McGovern   
et al., 2009). Overall, there was no correlation between the 
Figure 1.  Responsiveness to HCV antigens by CD4+ T cells from patients with acute HCV infection and spontaneously resolving versus per-
sistent viremia. (A) PBMCs obtained from patients within 6 mo of symptomatic HCV infection were stimulated for 6 d in vitro using 3 different recombi-
nant HCV proteins (NS3, NS4, and NS5) in the absence of rIL-2. Proliferation was measured using thymidine uptake and expressed as SI over negative 
control. Each dot represents a single patient. The dotted line delineates an SI value of 5 that is considered the cut-off for a positive proliferative response. 
(B and C) PBMCs obtained as in A were depleted of CD8+ T cells, and short-term CD4+ T cell lines were generated using recombinant HCV antigens and 
overlapping HCV peptides together with rIL-2. After 10–14 d, cell lines were tested for IFN- production, initially with pools of 20 overlapping peptides, 
and then, if positive, by single 20-mer peptides. (B) For each subject, the number of single peptides that tested positive is shown, plotted separately for 
the AR versus AC cohort. (C) The percentage of IFN-–secreting cells for each reactive cell line as determined by ICS and ro compare the relative size of 
the expanded HCV-specific populations between AR and AC subjects. (D) Detailed results for subject AC9 with acute infection followed by chronic viremia. 
The bar graph on the left shows results (in SI) from the standard proliferation assay without rIL-2 as in (A), showing no response against any of the HCV 
proteins, but robust proliferative responses against cytomegalovirus lysate, tetanus toxoid (TT) and phytohemagglutinin (PHA) controls. On the right, six 
dot blots showing positive ICS assays from the experiments outlined in B and C, confirming expansion of HCV-specific CD4+ T cells targeting six different 
epitopes in the same individual using short-term in vitro culture under the addition of rIL-2.JEM Vol. 209, No. 1 
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To confirm and extend these results, we performed CFSE 
proliferative assays after 7-d in vitro stimulation with a stan-
dardized HCV CD4+ T cell epitope peptide pool in the pres-
ence and absence of exogenous rIL-2. Although patients with 
AR infection had proliferative responses (in the standard LPA, 
but also in CFSE experiments without addition of rIL-2; Fig. 3, 
B and C), HCV-specific CD4+ T cells from subjects with early 
chronically evolving infection (<6 mo after onset of symptoms) 
only proliferated when stimulated with HCV peptides after 
addition of rIL-2 (Fig. 3 C). The importance of IL-2 for prolif-
eration of HCV-specific CD4+ T cells was further confirmed 
through an experiment in which in vitro blockade with an 
IL-2–blocking antibody (Lichterfeld et al., 2004) abrogated 
the HCV-specific proliferation in a patient with self-limited 
infection (Fig. 4). Finally, we also examined the effect of exog-
enous rIL-7 and/or rIL-21 on CD4+ T cell proliferation in-
duced by HCV antigens. In five AC and two acute spontaneously 
resolving (AR) subjects, we performed proliferative assays with 
rIL-2 or with rIL-2 in combination with rIL-7 and rIL-21. The 
additional cytokines did not increase the proliferative response 
in subjects that had detectable responses with rIL-2 alone. Nor 
did we detect responses in cases when the assay with rIL-2 was 
negative (unpublished data). Together, these data suggest that 
IL-2 is critical for the proliferative capacity of HCV-specific 
CD4+ T cells during early acute HCV infection.
Detection of HCV-specific CD4+ T cell responses  
is dependent on the duration of viremia in acute  
HCV infection with a chronic outcome
Because we had been mostly unable to detect any HCV-
specific CD4+ T cell responses in our 
previous studies analyzing subjects with 
established chronic infection (Chang 
et  al., 2001; Day et al., 2002, 2003; 
Schulze zur Wiesch et al., 2005), we 
aimed to establish how early the loss   
of CD4+ T cell responses occurs with 
persistence of viremia. Analyzing the 
cross-sectional data of in vitro expanded 
cell lines in acute infection, we found a 
significant inverse correlation between 
When we compared the repertoire of targeted epitopes in 
subjects with AR versus persisting infection, we observed 
similar patterns of recognition in both groups, with a major-
ity of responses located in the NS3 region (Fig. 2, A and B; 
and Table S2). Responses against previously reported immuno-
dominant epitopes frequently detected in resolved infection 
and thought to be crucial for resolution of infection (e.g., 
HCV aa 1241-1260, HCV aa 1771-1790; Fig. 2, A and B; 
Table S2; Diepolder et al., 1997; Wertheimer et al., 2003; 
Schulze zur Wiesch et al., 2005) were also detected in sub-
jects who ultimately failed to control viremia.
These data suggest that neither breadth nor specificity 
of the HCV-specific CD4+ T cell response during the early 
stages of infection determine the outcome of infection.
Supplementation of rIL-2 reverses the proliferative  
defects of HCV-specific CD4+ T cell responses in persisting 
acute HCV infection
To dissect which difference in the experimental setup de-
termined the improved proliferation of HCV-specific CD4+ 
T cell responses in our in vitro assays as compared with 
standard  LPA,  we  performed  a  CFSE  proliferation  assay 
combined with class II tetramer staining. This experiment 
demonstrated HCV-specific T cell proliferation only after 
peptide stimulation together with IL-2 support. HCV-specific 
cells of acute patient AC7 (week 16 after symptoms of infection) 
were unable to proliferate after restimulation with peptides 
p124 (HCV aa1241-1260) and p177 (HCV aa1771-1790) 
alone, but proliferated vigorously after addition of recombi-
nant rIL-2 to the cell culture (Fig. 3 A).
Figure 2.  Frequency of detection of 
single HCV CD4+ epitopes using short-
term in vitro culture with the addition of 
rIL-2. (A and B) The relative location of each 
epitope detected in the assays from Fig. 1 
(B and C) within the HCV polyprotein and 
the frequency with which the respective 
peptide was recognized in the cohort of  
patients with self-limited (AR) and chronic 
(AC) infection. The six most frequently rec-
ognized peptides are marked with their exact 
location in the HCV protein sequence. More 
detailed information on all epitopes detected 
in each individual patient of the cohort can 
be found in Table S2.66 Kinetics of T cell dysfunction in HCV infection | Schulze zur Wiesch et al.
and HCV aa 1771-1790; Diepolder et al., 1997; Day et al., 
2002; Wertheimer et al., 2003; Schulze zur Wiesch et al., 
2005, 2007).
In contrast, for patients with spontaneous resolution of 
HCV we observed no such correlation, and the number of 
HCV-specific CD4+ T cell responses detected in the in vitro 
cell culture system remained stable over time (Fig. 5 B).   
Indeed, we and others were able to recover in vitro HCV-
specific CD4+ T cell responses in patients with spontaneously 
controlled infection many months and even years after reso-
lution of HCV viremia (Chang et al., 2001; Schulze zur 
Wiesch et al., 2005; Smyk-Pearson et al., 2006).
Direct ex vivo tetramer analysis confirms 
circulating HCV-specific CD4+ T cells during 
early acute infection irrespective of outcome
To confirm the results obtained with in vitro cul-
ture of HCV-specific CD4+ T cells, we analyzed 
the number of detected responses and time elapsed between 
the onset of symptoms and performance of the experiment in 
subjects with chronically evolving infection; only very few re-
sponses could be expanded after a 10–12-wk duration of vi-
remia (Fig. 5 A; P < 0.02) and none after 6 mo of viremia (not 
depicted). The observation of HCV-specific CD4+ T cell re-
sponses early in AC infection, followed by a loss of the re-
sponse with persisting viremia held true for all HCV CD4+  
T cell specificities, including responses against two HCV epi-
topes that we and others had previously described as immuno-
dominant in resolving HCV infection (HCV aa 1241-1260 
Figure 3.  HCV-specific proliferation of virus-specific CD4+ T cells in the presence or absence of IL-2. (A) PBMCs of an early time point from  
patient AC7 with AC HCV infection were labeled with CFSE dye and stimulated with no peptide () or peptides p124 (aa 1241-1260) and p177 (aa 1771–
1790) in the presence (left) or absence (right) of rIL-2. After 7 d, cells were stained with HCV-specific tetramers Tet124 and Tet177. (B) CFSE proliferation assay 
in a patient with acute HCV infection and self-limited disease. PBMCs were stained with CFSE dye and stimulated with HIV peptides (control peptides) or a 
pool of the six most frequently detected immunodominant HCV peptides (Fig. 2) for 7 d with or without addition of rIL-2. (C) Summary of the CFSE prolifera-
tion experiments performed as in A on six patients (filled circles) with AC infection and six patients (filled squares) with AR infection either in the absence or 
presence of IL-2. (SI, stimulation index with the frequency of proliferating cells without addition of peptide and rIL-2 as the denominator).
Figure 4.  Abortion of HCV-specific T cell prolifera-
tion by an anti–IL-2 blocking antibody. CFSE assay in 
a patient with resolution of the acute infection. PBMCs 
from a patient with resolved HCV infection were depleted 
of CD8+ T cells, stained with CFSE dye, and stimulated 
with recombinant c200 (NS3+NS4) protein in the pres-
ence of IL-2–blocking antibody or isotype control. At day 7, 
the number of CFSElow cells was assessed by flow cytom-
etry. Superoxide dismutase served as negative control 
and phytohemagglutinin and c200 plus IL-2 served as 
positive controls.JEM Vol. 209, No. 1 
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Testing the first available PBMC sample after infection 
for each subject, at least one ex vivo tetramer response was 
detectable in 37 of 40 subjects with acute infection (93%).   
Of those, 14/17 patients with AC infection and 23/23 of   
patients with AR infection showed at least one tetramer 
response. Overall, we detected 55 of 61 (90%) individual 
positive tetramer tests, with 20/26 positive tetramer re-
sponses in patients with AC infection. In patients with AR 
infection, we detected 35/35 individual tetramer responses, 
and these were typically of higher frequency than those in 
subjects with persisting viremia. In addition, the three sub-
jects without any detectable tetramer response all devel-
oped  persistent  viremia.  However,  these  patients  could 
only be tested at later time points (>75 d after the onset of 
symptoms), a timeframe in which the in vitro expansion 
assays usually do not recover HCV 
CD4+ T cell responses in AC infec-
tion either.
Tetramer assays also allowed us to 
examine the expression of memory   
T cell markers on HCV-specific CD4+ 
T  cell  populations.  Overall,  we  saw 
low expression of CD127 in all sub-
jects during early infection, in contrast 
to responses after spontaneous resolu-
tion of infection that uniformly ex-
press the IL-7 receptor (unpublished 
data). The activation marker CD38 
these cells directly ex vivo, using class II tetrameric complexes. 
Based on previous studies (Gerlach et al., 2005; Schulze zur 
Wiesch et al., 2005; Kasprowicz et al., 2008) we were able to 
synthesize a total of 8 class II tetramers for some of the most 
frequently targeted HCV epitopes restricted by 5 different 
human leukocyte antigen (HLA) molecules (Table S3). In Fig. 6 A, 
representative flow cytometry dot plots of tetramer stainings for 
patients AC1 with chronically evolving course and AR3 with 
AR course are depicted. Because only a limited number of sub-
jects in the original cohort of 31 patients expressed HLA mole-
cules for which we have class II tetramers available, we performed 
tetramer analysis on PBMCs from an additional 18 patients with 
documented acute infection (Table S1). This allowed us to test 
for a total of 61 HCV CD4+ T cell specificities directly ex vivo 
in 40 patients using HLA-matched class II tetramers.
Figure 5.  Time dependency of detection 
of HCV-specific CD4+ T cell responses in 
patients with acute HCV infection. The 
number of HCV-specific CD4+ responses de-
tected in HCV-antigen stimulated short-term 
T cell lines with rIL-2 (as shown in Fig. 1 B) 
was plotted against the time elapsed between 
symptom onset and sampling of blood for the 
experiment in AC infection (A) and patients 
with AR course (B). Each square represents 
the number of HCV peptide-specific CD4+  
T cell responses of a single patient.
Figure 6.  Analysis of the frequency of 
HCV-specific CD4+ T cells by direct ex vivo 
class II tetramer staining in patients with 
acute HCV infection. (A) Sample dot blots 
for ex vivo tetramer staining with tetramer 
p177 in a patient with self-limited acute HCV 
infection (AR3) and a patient with chronically 
evolving HCV infection (AC1). (B) The ex vivo 
frequencies of all HCV MHC class II tetra-
mers stainings performed on all samples of a 
total of 38 patients are plotted against the 
time elapsed between onset of symptoms  
and sampling of blood for each assay,  
depicted separately for AR infection and  
AC infection.68 Kinetics of T cell dysfunction in HCV infection | Schulze zur Wiesch et al.
Figure 7.  Longitudinal assessment of HCV-specific CD4+ T cell responses by MHC class II tetramer staining. Detailed longitudinal results for 
three subjects with different clinical courses using standard proliferation assay and short-term cell lines with rIL-2, as in Fig. 1 D, as well as tetramer 
assays as shown in Fig. 6 (A and B). Frequencies of two class II tetramers (Tet124 and Tet177; triangles) over time for patient AR8 with AR infection 
blotted together with HCV viral load (gray; A) and as individual dot blots for each time point (B). (bottom) Results for the in vitro standard prolifera-
tion assay for comparison with the direct ex vivo tetramer results above. (C–F) Patients AC7 and AC10 were both diagnosed with acute HCV infection 
and persisting viremia. AC7 was treated at an early time point after developing symptomatic disease, whereas AC10 was treated only almost a year JEM Vol. 209, No. 1 
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method in AC subjects. In contrast, although the magnitude 
of individual responses decreases over time in AR infection, 
HCV-specific MHC class II tetramer+ T cells remain detect-
able directly ex vivo up to 1 yr and longer. Overall, the fre-
quencies of tetramer+ populations are significantly higher   
in subjects with AR infection compared with those in indi-
viduals with persisting viremia. However, during the first 
30–60 d of observation, these differences are much less pro-
nounced than at later time points, and one observes a wide 
overlap between the two groups. Together, these data show 
that HCV-specific CD4+ T cell responses have two distinct 
fates. Spontaneous resolution of infection is associated with 
lasting CD4+ T cell populations that retain or even increase 
their proliferative capacity. In contrast the expansion of 
HCV-specific CD4+ T cells in persistent infection is short-
lived, and the cell populations are already limited in their 
proliferative capacity at early time points, and then are com-
pletely undetectable in the blood by ex vivo tetramer tech-
nology or by in vitro expansion.
We were also able to follow subjects with persisting acute 
infection  through  antiviral  therapy,  with  some  subjects   
being treated relatively early (<24 wk after onset of symptoms; 
Fig. 7, C and D) and others receiving delayed treatment for   
a variety of clinical reasons (>24 wk after onset of symptoms; 
Fig. 7, E and F). Not only did tetramer responses reemerge 
after successful early treatment within the first 3 mo after   
onset of symptoms (Fig. 7 C and Fig. 8 B), but, in parallel, we 
were also able to detect broad responses through the assays 
using in vitro stimulation followed by confirmation of HCV-
specific CD4+ T cell responses with ICS (Fig. 7 D and Fig. 8 A). 
In  contrast,  successful  therapy  during  the  subacute  phase 
(later than 6 mo after onset of symptoms) or untreated AC 
infection were not associated with a reconstitution of HCV-
specific CD4+ T cell responses (Fig. 7, E and F; and Fig. 8, A 
and B), similar to what we observe in patients after successful 
treatment in the chronic phase (not depicted). Overall, our 
data suggest that the deletion of HCV-specific CD4+ T cell 
responses is directly dependent on HCV viremia and that re-
moval of the virus by antiviral therapy is able to prevent the 
complete loss of HCV-specific CD4+ T cell responses during 
a short window of opportunity.
DISCUSSION
There is a general consensus that vigorous CD4+ T cell pro-
liferative responses are correlated with spontaneous resolu-
tion of HCV infection. Since the initial study by Diepolder 
et al. (1995), this observation has been confirmed by a multi-
tude of studies (Chang et al., 2001; Schulze zur Wiesch et al., 
was highly expressed during early infection in all patients, but 
was subsequently lost with the emergence of CD127+ mem-
ory cells. Expression of the inhibitory T cell receptor pro-
grammed death 1 was uniformly high, independent of HCV 
outcome, as we have previously shown (Kasprowicz et al., 
2008). Overall these results are similar to what we have ob-
served for HCV-specific CD8+ T cell responses (Lucas et al., 
2004; Kasprowicz et al., 2008, 2010).
HCV-specific CD4+ T cell responses are deleted  
from the blood during persistence of HCV viremia, but early 
initiation of therapy can preserve CD4+ T cell populations
We were unable to detect CD4+ T cell responses by in vitro 
expansion once HCV viremia had been established for >6 mo, 
despite  addition  of  exogenous  rIL-2  (unpublished  data; 
Schulze zur Wiesch et al., 2005). To determine whether this 
failure of detection was based on increasing deficits in prolif-
erative capacity of HCV-specific T cells or on physical dele-
tion of this T cell population from the blood, we longitudinally 
analyzed the kinetics of the CD4+ T cell response during 
acute HCV ex vivo using class II tetramers. In AR infection 
(Fig. 7 A), a strong expansion of HCV-specific CD4+ T cells 
was followed by a quick contraction of these populations   
after resolution of HCV, but core populations of tetramer-
positive cells remained detectable long after the acute phase 
of infection. Throughout the observation period, prolifera-
tive responses remained strongly positive and cells were 
readily expandable for years.
In persisting acute infection (Fig. 7, C and E) a different 
picture emerged. Tetramer+ cells were detectable only ini-
tially during acute infection and then disappeared completely 
from the blood with persisting viremia, even if viral loads 
were relatively low (Fig. 7 C). Similarly, at early time points 
we were able to expand HCV-specific CD4+ T cell popula-
tions and confirm by ICS in these subjects, but not at later 
time points, when ex vivo tetramer assays were also negative. 
The standard LPA assays that we performed in parallel re-
mained negative throughout the observation period.
Fig. 6 B summarizes the results for subjects with AC ver-
sus AR infection separately, plotting the results from all tet-
ramer assays we performed in relationship to the day after 
onset of symptoms the sample was obtained. These ex vivo 
results look strikingly similar to the results obtained using in 
vitro HCV CD4+ T cell lines (Fig. 5, A and B), in that early 
during infection we see universally positive responses, fol-
lowed by a rapid decline and disappearance of HCV-specific 
populations with persisting viremia. Barely any responses are 
detectable later than 3 mo after onset of symptoms by either 
after the onset of symptoms. Both achieved a sustained virological response (SVR). Frequencies for detected tetramer responses (triangles) are plotted 
together with HCV viral load (gray) and the treatment period (red) in the top panel of C for AC7 and E for AC10. Asterisks in E mark time points at 
which tetramer assays were negative even with more sensitive tetramer staining protocols based on magnetic bead capture enrichment (Day et al., 
2003). (C and E, bottom) Results from the standard proliferation assay over the same time periods as the tetramer results above. (D and F) ICS results 
detecting IFN- secretion are shown for short-term cultures at different time points of infection using rIL-2 and single HCV peptide that had tested 
positive in the first available blood sample.
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3 and 6 mo after onset of symptoms) fully account for the 
trend toward somewhat fewer responses in persons with   
persisting infection. It seems very likely that analysis of subjects 
that were all recruited within the initial 8–12 wk after infec-
tion would show even less distinguishable results of the CD4+ 
T cell response over different clinical outcomes. Our data 
indicate that the progression of acute HCV infection into 
chronic hepatitis C is not a result of a primary failure to 
mount a broad CD4+ T cell response, but is caused by sec-
ondary mechanisms leading to the collapse of the HCV-
specific CD4+ T cell response. Furthermore, our data highlight 
the importance of studying well-defined cohorts of early 
acute HCV infection (Cox et al., 2009) and of carefully dif-
ferentiating between results obtained in the true acute phase of 
infection versus those in the subacute (early chronic) phase, 
e.g., between 6 and 12 mo after infection, as the CD4+ T cell 
response is clearly already profoundly altered at these later 
time points. Only at the earliest time points will it be possible 
to identify key mechanisms contributing to the outcome of 
infection, rather than just studying the consequences of viral 
persistence or control.
Our experimental approach allowed us to define not just 
the HCV protein targets of the CD4+ T cell response but 
also to identify for each subject the individual peptides that 
were recognized. The results confirm our previous study of 
resolved infection in that NS3, NS4, and NS5 are most fre-
quently targeted, with 6 peptides resembling immunologi-
cal “hotspots” that were recognized by >25% of subjects 
with  spontaneous  resolution  of  viremia.  Importantly,  we 
were able to detect these dominant responses in patients 
with early acute HCV infection that were not successful in 
controlling viremia. The recognition pattern in these sub-
jects was very similar to that found in AR infection, raising 
the possibility that control of viremia is more a consequence 
of the quality, timeliness, kinetics, and maintenance of the 
CD4+ T cell response and not targeting of certain immuno-
dominant epitopes.
2005; Smyk-Pearson et al., 2006). Nevertheless, little is known 
about the quantity and the quality of the early CD4+ T cell 
response beyond the ability of HCV-specific CD4+ T cells to 
proliferate against HCV proteins in vitro in standard LPA   
assays. It also remains unknown whether HCV-specific CD4+ 
T cell responses are generally absent in chronically evolving 
infection (with the exception of subjects with complete tem-
porary control or patients that previously spontaneously cleared 
a heterologous HCV genotype), or whether responses are 
present  but  functionally  disabled  in  persisting  viremia.   
Another important question is whether targeting of certain 
epitopes (Diepolder et al., 1997; Schulze zur Wiesch et al., 
2005; Smyk-Pearson et al., 2006) is necessary or sufficient to 
achieve a favorable outcome. In the present study, we have 
combined distinct methods characterized by high sensitivity, 
specificity, and resolution to characterize the CD4+ T cell re-
sponse in a large cohort with early acute HCV infection and 
diverging clinical outcomes.
Our  first  surprising  finding  is  that  the  breadth  of  the 
CD4+ T cell response during early acute infection is compa-
rable between patients who become chronically infected and 
those with spontaneously resolving viremia. In all 31 subjects 
studied, we detected HCV-specific CD4+ T cells in HCV-
stimulated T cell lines, with up to 26 epitopes targeted in a 
single individual. Although there was a trend toward a 
greater number of epitopes targeted in self-limited infection, 
this is most likely explained by the important observation   
that with persisting infection the breadth of the response is 
tightly correlated to the time elapsed after infection, as   
responses become undetectable within weeks (Fig. 5 A,   
Fig. 6 B, and Fig. 7 E). In contrast, the HCV-specific CD4+ 
T cell response repertoire in AR infection remains stable 
for months, and as we and others have previously shown, 
even years after infection (Takaki et al., 2000; Chang et al., 
2001; Day et al., 2002). Hence, patients with persisting infec-
tion who were recruited into our study during the second 
half of our recruitment window for acute infection (between 
Figure 8.  Analysis of HCV-specific CD4+ 
T cell responses in patients with AC infec-
tion and a sustained virological response 
(SVR) after early versus late induction of 
antiviral treatment. (A) PBMCs obtained 
after successful antiviral therapy of acute 
infection and either early (<6 mo after symptom 
onset; n = 5) or late (<6 mo after symptom 
onset; n = 3) initiation of treatment were 
depleted of CD8+ T cells, stimulated with re-
combinant antigens and overlapping peptides, 
and after 10–14 d the number of single pep-
tides eliciting an IFN- response was mea-
sured (as in Fig. 1 B). Each dot represents  
the number of different responses in each 
patient. (B) Ex vivo HCV MHC class II tetramer 
frequencies before and after treatment. Fre-
quencies of HCV-specific CD4+ T cells were 
assessed before and after treatment using HLA class II tetramer staining in subjects with chronically evolving infection who were treated early. Untreated 
patients with AC served as controls. Each dot or square represents one tetramer response in a single individual.JEM Vol. 209, No. 1 
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lack of detectable responses in PBMCs is at least partially 
caused by compartmentalization to the liver. In contrast to 
the CD8+ T cell response, for which there is ample evidence 
for this phenomenon (Nelson et al., 1998; Wong et al., 1998; 
Spangenberg et al., 2005; Neumann-Haefelin et al., 2008), 
little is known about compartmentalization of HCV-specific 
CD4+ T cells in chronic infection (Minutello et al., 1993; 
Penna et al., 2002). However, in our own preliminary stud-
ies, we could barely detect any intrahepatic HCV-specific 
CD4+ T cell responses using in vitro expansion protocols   
(n = 10 patients; unpublished data), despite our observation 
in the present study that the breadth of the peripheral CD4+  
T cell response against HCV is generally greater than that of the 
CD8+ T cell response in acute infection (Lauer et al., 2005).
Another explanation for the collapse of the HCV-specific 
CD4+ T cell response in patients with acute HCV infection 
and persisting viremia could be in the development of viral 
escape mutations leading to a lack of stimulation of the T cell 
receptor. We have started to generate longitudinal viral se-
quences  corresponding  to  the  CD4+  epitopes  targeted  by   
individuals with chronic evolution of infection. Our prelimi-
nary results for 13 epitopes in 8 individuals do not indicate 
any viral evolution that could be attributed to CD4+ T cell 
responses (unpublished data), in contrast to observations for 
CD8+ responses (Timm et al., 2004; Cox et al., 2005b; 
Tester et al., 2005). Together with data from the chimpanzee 
model of HCV infection (Fuller et al., 2010), this suggests a 
limited role for viral escape mutations in the loss of the CD4+  
T cell response in acute HCV infection that persists chronically.
Our observations in subjects undergoing antiviral therapy 
support the theory that the loss of proliferative function fol-
lowed by deletion of HCV-specific CD4+ T cells is directly 
associated  with  HCV  viremia.  After  successful  control  of   
viremia in early therapy, we were able to continuously detect 
HCV-specific CD4+ T cell responses against HCV both by 
extended in vitro culture and ex vivo by class II tetramers, 
comparable to what we have observed after spontaneous res-
olution of infection (Day et al., 2003; Schulze zur Wiesch   
et al., 2005). In contrast, HCV-specific CD4+ T cell responses 
were detectable neither by tetramer technology nor by in 
vitro cell lines and ICS in patients that had been treated at 
later stages of chronically evolving infection (>24 wk after 
onset of disease), suggesting that damage to the HCV-specific 
CD4+ T cell response occurs very early with persistent vire-
mia, progresses rapidly, and becomes difficult to revert once 
chronicity has been established.
It is also noteworthy that, even with early therapy, the 
recovery of the CD4+ T cell response is not necessarily 
functionally complete; in patient AC10 (Fig. 7, C and D), 
HCV-specific  responses  remained  undetectable  by  stan-
dard proliferation assay (without IL-2), but were detectable 
after in vitro expansion under addition of IL-2 and also di-
rectly ex vivo using class II tetramers. In subjects who were 
successfully treated at later stages of acute infection (>6 mo after 
symptoms), we could not detect CD4+ T cell responses against 
HCV by any method (Fig. 7, E and F; and Fig. 8, A and B). 
The in vitro cell culture assay used for this study differed 
from the standard proliferation assay (LPA) by three impor-
tant parameters: a higher input number of cells per test, an   
in vitro incubation time that is doubled, and the addition of   
rIL-2 to the culture. We sought to further define the rele-
vance of these changes by performing additional CFSE experi-
ments in which we compared the assay when performed with 
and without the addition of rIL-2. The results suggest that 
rIL-2 is a critical factor for the enhanced sensitivity of this assay 
and promote the hypothesis that a lack of IL-2 support is an 
important step in the failure to maintain CD4+ T cell re-
sponse against persisting viruses (Iyasere et al., 2003; Lichterfeld 
et al., 2004; Klenerman and Hill, 2005; Semmo et al., 2005).
Based  on  our  previous  comprehensive  screening  for 
HCV CD4+ T epitopes (Schulze zur Wiesch et al., 2005), we 
constructed a set of novel class II tetramers that enabled us to   
detect HCV-specific CD4+ T cells directly ex vivo, with no 
need for in vitro culture. In contrast to previous studies, we 
were able to forego enrichment of the tetramer+ cells via 
magnetic beads caused by the higher numbers of specific cells 
during acute infection and improved quality of the tetrameric 
complexes.  These  experiments  confirmed  the  presence  of 
significant numbers of HCV-specific CD4+ T cells during 
the early stages of acute infection, irrespective of infection 
outcome and usually targeting multiple epitopes. Our re-
sults for several epitopes restricted by different class II mole-
cules confirm and extend the findings by Lucas et al. (Lucas 
et al., 2007) and Diepolder (Ulsenheimer et al., 2006) who 
previously described tetramer responses in acute persisting 
HCV infection using a single class II tetramer restricted by 
HLA-DR1.
Even during early acute infection, frequencies of the   
ex vivo HCV-specific CD4+ T cells were somewhat lower in 
subjects with acute persisting infection; however, these dif-
ferences seem to be gradual and there was substantial overlap 
between both groups. This difference could be explained by 
the distinct dynamics of the tetramer+ cells that become so 
rapidly undetectable (usually within weeks) in persisting vire-
mia (Fig. 6 B and Fig. 7 E); thus, it seems possible that at the 
earliest stages of infection, before individuals were recruited 
into our study, the frequency and vigor of HCV-specific 
CD4+ T cells might have been comparable between the 
different patient groups. Alternatively, a marked difference in 
the vigor of the CD4+ T cell response at the earliest days of 
infection might be critical for the outcome of infection. To fully 
define the importance of the magnitude of HCV-specific 
CD4+ T cell responses, it would be helpful to study patients 
from prospective cohorts of acute HCV infection (Cox et al., 
2005a), potentially allowing analysis of even earlier events   
after infection.
In contrast to the scenario in acute infection with persist-
ing viremia, HCV-specific CD4+ T cell populations contract 
after spontaneous resolution of infection, but a core popula-
tion remains detectable, often for years. Although our cur-
rent hypothesis is that HCV-specific CD4+ T cells are mostly 
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HCV peptides and recombinant HCV proteins. Peptides were synthesized 
corresponding to the amino acid sequences of the HCV-1a strain HCV-1 (avail-
able from GenBank/EMBL/DDBJ under accession no. M62321). A total of 301 
20-mers overlapping by 10 aa and spanning the entire polyprotein were used for 
screening responses (Day et al., 2002). Additional peptides were synthesized ac-
cording to autologous viral sequences. Recombinant HCV proteins used in this 
study were expressed as C-terminal fusion proteins with human superoxide   
dismutase  in  Saccharomyces  cerevisiae  or  Escherichia  coli  and  were  provided  by   
M. Houghton (Novartis Vaccines and Diagnostics). These proteins were derived 
from the HCV-1 sequence and encoded core (C22-3 aa 2 to 120), NS3 (C33C 
aa 1192–1457), NS4 (C100.3 aa 1569–1931), NS3/NS4 (C200 aa 1192–1931), 
and NS5 (NS5 aa 2054–2995).
HLA typing. DNA for typing was extracted using the PUREGENE DNA 
isolation kit for blood (Gentra Systems) according to the manufacturer’s instruc-
tions. HLA class II typing was performed at the MGH Tissue Typing Laboratory 
using sequence-specific primer PCR, as previously described (Bunce et al., 
1995). High-resolution HLA class II typing was performed by Dynal Biotech 
HLA Diagnostics (Invitrogen) using sequence-specific primer PCR.
Sequencing of autologous virus. Sequences were determined as previ-
ously described (Timm et al., 2004; Schulze Zur Wiesch et al., 2007). In 
brief, viral RNA was extracted from plasma using the vRNA extraction kit 
(QIAGEN). Genotype-specific primers were designed based on alignments 
of all available sequences from public HCV databases. Reverse transcription 
was performed with the QIAGEN One-Step RT-PCR kit, followed by 
nested PCR using Titanium Taq DNA polymerase (CLONTECH Labora-
tories). PCR fragments were gel- or PCR-purified (QIAGEN QIA-Quick 
Gel Extraction/PCR Purification kit), and the population was sequenced 
bidirectionally on an ABI 3100 PRISM automated sequencer (Applied Bio-
systems). Sequencher (Gene Codes) and MacVector 4.1 (Oxford Molecular) 
software programs were used to edit and align sequences.
Lymphocyte proliferation assays. Lymphocyte proliferation assays were 
performed as described previously (Day et al., 2002; Lauer et al., 2002) using 
c22.3, c33c, c100.3, C200 and NS5 HCV proteins (Chiron) at concentra-
tions of 10 µg/ml (Day et al., 2002). CFSE proliferation assays were per-
formed as previously described (Lichterfeld et al., 2004; Kasprowicz et al., 
2008; Schulze Zur Wiesch et al., 2009). Where indicated, IL-2–neutralizing 
antibodies (clone MQ1-17H12; BD) or isotype control antibodies (clone 
A4A; Neomarkers) were added at 10 µg/ml.
Bulk stimulation of PBMCs. 15-20 million fresh or thawed PBMCs were 
depleted from CD8+ cells according to manufacturer’s instructions (Invitro-
gen) and the CD8+-depleted cells were stimulated with 1 µg/ml recombi-
nant HCV antigens (either C22-3, C33C, C100, C200, or NS5) in 2 ml of 
R10 medium supplemented with recombinant IL-2 (50 U/ml) as previously 
described (Day et al., 2002; Schulze zur Wiesch et al., 2005, 2007). Alterna-
tively, for the regions of the HCV genome for which recombinant antigens 
were not available (E1, E2, p7, and NS2) PBMCs were stimulated with 
overlapping 20-mer peptides (1 µg/ml each) in pools of 10 peptides.
To test the effect of additional stimulation with different interleukins, further 
HCV CD4+ T cell cultures were generated and rIL-7 and rIL-21 were added at 
day 1 and 3 at a final concentration of 50 ng/ml. After 10–14 d, the cells were   
assayed for IFN- production by ICS in response to stimulation with pools of 
overlapping 20-mer HCV peptides. After 10–14 d, cells were assayed for IFN- 
production by ELISpot or ICS in response to stimulation with HCV peptides.
ELISpot assay. ELISpot assays were performed as previously described (Lauer 
et al., 2002, 2005; Schulze zur Wiesch et al., 2005). Responses were considered 
positive if the number of spots was three times greater than the background; phy-
tohemagglutinin served as a positive control. All positive responses were recon-
firmed by intracellular cytokine assay after stimulation with the specific peptide.
Intracellular IFN- staining and flow cytometry. In brief, 5 × 105 bulk 
expanded PBMCs were stimulated with 4 µM peptide and anti-CD28 and 
anti-CD49d MAbs (1 µg/ml each; BD) at 37°C and 5% CO2 for 1 h before 
Together this suggests that the loss of CD4+ T cell function 
occurs before the physical deletion of the T cells and that 
fully functional CD4+ T cell responses are not required for 
the success of antiviral therapy (Rahman et al., 2004; Lauer   
et  al.,  2005;  Barnes  et  al.,  2009).  Whether  the  rescue  of   
CD4+ T cell responses through early treatment would be 
beneficial during a subsequent reexposure to HCV remains 
an open question.
One of the remaining challenges in unraveling the mystery 
of the secondary failure of the CD4+ T cell response in AC HCV 
infection will be to define the reasons for the functional differ-
ences of the HCV-specific CD4+ T cells, and also to define the 
exact mechanisms leading to deletion of these cells. Despite   
our ability to visualize HCV-specific T cells directly ex vivo by 
tetramer technology, the extremely low frequencies of these cell 
populations, even in the acute phase of infection, has prevented a 
more detailed ex vivo functional analysis at this time. However, 
based on the results from this study, we have now successfully   
begun to live-sort HCV-specific CD4+ T cells using tetramers 
for use in large scale gene expression analyses that have now   
become feasible even on very low cell numbers.
In summary, we demonstrate here for the first time that the 
HCV-specific CD4+ T cell response in persisting early acute 
infection is comparable in breadth, vigor, and repertoire to that 
observed in spontaneously resolving infection. Our findings 
challenge the current paradigm that suggests an initial failure to 
prime CD4+ T cell responses as the primary cause of viral per-
sistence in most patients. Rather, persistent viremia is associ-
ated with a secondary failure of the CD4+ T cell response, 
which is characterized by early functional deficits and, later, 
complete deletion of the CD4+ T cell response from the blood 
through mechanisms not yet fully understood. Interestingly, 
the failure of the CD4+ T cell response can at least be partially 
reversed through early antiviral therapy, suggesting a direct 
role of HCV in subverting the immune response (Folgori et al., 
2006; Badr et al., 2008). To understand the requirements of a 
protective CD4+ T cell immune response to be elicited by a 
successful HCV vaccine or immunotherapy, we must define 
the critical mechanisms that lead to the early functional impair-
ment followed by the physical deletion of HCV-specific CD4+ 
T cells in the context of persisting viremia.
MATERIALS AND METHODS
Patients. Acute hepatitis C was diagnosed by documented seroconversion to 
anti-HCV antibodies or all of the following: acute onset of hepatitis in previously 
healthy individual, aminotransferases at least 10× the upper limit of normal, ex-
clusion of other infectious, metabolic, or toxic causes of hepatitis and recent ex-
posure or source of infection identified (Corey et al., 2006; McGovern et al., 
2006). 18 patients with spontaneously controlled HCV infection and 13 patients 
with chronically evolving HCV infection were enrolled in this study (Table I). 
Because only a limited number of subjects in this cohort of 31 patients expressed 
HLA class II molecules, allowing HCV class II tetramer analysis, we recruited a 
second cohort of 18 subjects for tetramer studies (Table S1). These individuals 
fulfilled the same criteria for acute HCV infection, and all expressed class II mol-
ecules for which HCV tetramers were available. The study was approved by the 
Institutional Review Boards of the Massachusetts General Hospital, the Lemuel 
Shattuck Hospital, and the Oswaldo Cruz Institute. All patients gave written in-
formed consent.JEM Vol. 209, No. 1 
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with surface antibodies, allophycocyanin-conjugated anti-CD3, and peridin-
chlorophyll protein-conjugated anti-CD4 (BD) at room temperature for 20 
min. After washing, the PBMCs were fixed and permeabilized (Invitrogen), 
and the FITC-conjugated anti–IFN- mAb (BD) were added as previously 
described (Day et al., 2002; Rosen et al., 2002; Lauer et al., 2004; Schulze 
zur Wiesch et al., 2005). Cells were then washed and analyzed on a FACS-
Calibur flow cytometer using CELLQuest software (BD).
MHC class II tetramer staining of PBMCs. MHC class II tetramer stain-
ing was performed as previously described (Day et al., 2003; Kasprowicz et al., 
2008). Cells (either fresh PBMCs, cryopreserved PBMCs, or cells from a 
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